Satellos
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Bay St Ste 2800, Toronto, Ontario, M...Phone Number
(647) 660-1780Website
www.satellos.comRevenue
-Stock Symbol
MSCLFIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Satellos
Satellos is dedicated to improving the treatment of Duchenne muscular dystrophy and other muscle diseases by developing small molecule therapeutics that restore the body's ability to regenerate muscle. Their innovative MyoReGenX platform focuses on reactivating the natural repair processes disrupted by the absence of dystrophin. The company targets AAK1, a protein crucial for guiding muscle stem cells in tissue repair. Satellos aims to enhance outcomes for individuals affected by degenerative muscle conditions through their research and therapeutic advancements.Explore more
Satellos Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Satellos your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Satellos is spiking on competitors!
Satellos, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Satellos recently announced quarterly report
Product Launch: Get notified when Satellos launches new products
Congratulate Masked Content for being promoted to Masked Content at Satellos
Click to see if Satellos had a recent Job posting/layoffs
Check if Satellos has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Satellos has new funding data
Recommended Actions
Reach out to Masked Content who joined Satellos as Masked Content
Find 3 more new buyers
Compare Similar Companies to Satellos
Compare insights from companies similar to Satellos, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Satellos is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Satellos is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Satellos.
Satellos financials insights
Gather financial insights about Satellos, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Corporate Investment
$1M
2024
Other Financing Round
$40M
Satellos Tech Stack
A closer look at the technologies used by Satellos
Most Recent Scoops
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Satellos News & Media
Satellos to Present Clinical Program Updates at ICNMD 2026
TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that new data from its SAT-3247 clinical development program will be featured at the 19th International Congress on Neuromuscular Diseases (ICNMD), taking place July 7–11, 2026, in Florence, Italy, at Fortezza da Basso.Satellos Bioscience Announces Results of Annual Meeting of Shareholders
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 (the “Meeting”).Satellos to Participate in Upcoming Investor Conferences
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that members of the Company management team will participate in the following investor conferences in June.Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Satellos
Sign Up For FreeTo access detailed company insights
Satellos is dedicated to improving the treatment of Duchenne muscular dystrophy and other muscle diseases by developing small molecule therapeutics that restore the body's ability to regenerate muscle. Their innovative MyoReGenX platform focuses on reactivating the natural repair processes disrupted by the absence of dystrophin. The company targets... Read More
